Search Results - "Pateman, Anthony J"

Factor Xa Inhibitors:  S1 Binding Interactions of a Series of N-{(3S)-1-[(1S)-1-Methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides by Chan, Chuen, Borthwick, Alan D, Brown, David, Burns-Kurtis, Cynthia L, Campbell, Matthew, Chaudry, Laiq, Chung, Chun-wa, Convery, Máire A, Hamblin, J. Nicole, Johnstone, Lisa, Kelly, Henry A, Kleanthous, Savvas, Patikis, Angela, Patel, Champa, Pateman, Anthony J, Senger, Stefan, Shah, Gita P, Toomey, John R, Watson, Nigel S, Weston, Helen E, Whitworth, Caroline, Young, Robert J, Zhou, Ping

“…Factor Xa inhibitory activities for a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides with different P1…”
Get full text

The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs by Watson, Nigel S., Adams, Carl, Belton, David, Brown, David, Burns-Kurtis, Cynthia L., Chaudry, Laiq, Chan, Chuen, Convery, Máire A., Davies, David E., Exall, Anne M., Harling, John D., Irvine, Stephanie, Irving, Wendy R., Kleanthous, Savvas, McLay, Iain M., Pateman, Anthony J., Patikis, Angela N., Roethke, Theresa J., Senger, Stefan, Stelman, Gary J., Toomey, John R., West, Robert I., Whittaker, Caroline, Zhou, Ping, Young, Robert J.

“…The discovery of potent and long-acting series of orally available factor Xa inhibitors with tetrahydroisoquinoline and benzazepine motifs is described. The…”
Get full text

Structure- and property-based design of factor Xa inhibitors: Pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs by Young, Robert J., Campbell, Matthew, Borthwick, Alan D., Brown, David, Burns-Kurtis, Cynthia L., Chan, Chuen, Convery, Máire A., Crowe, Miriam C., Dayal, Satish, Diallo, Hawa, Kelly, Henry A., Paul King, N., Kleanthous, Savvas, Mason, Andrew M., Mordaunt, Jackie E., Patel, Champa, Pateman, Anthony J., Senger, Stefan, Shah, Gita P., Smith, Paul W., Watson, Nigel S., Weston, Helen E., Zhou, Ping

“…The synthesis and profiles of a series of fXa inhibitors with acyclic alanyl amide P4 motifs is described, which includes potent examples showing highly…”
Get full text

Structure and property based design of factor Xa inhibitors: Pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs by Young, Robert J., Adams, Carl, Blows, Mike, Brown, David, Burns-Kurtis, Cynthia L., Chan, Chuen, Chaudry, Laiq, Convery, Máire A., Davies, David E., Exall, Anne M., Foster, Graham, Harling, John D., Hortense, Eric, Irvine, Stephanie, Irving, Wendy R., Jackson, Steve, Kleanthous, Savvas, Pateman, Anthony J., Patikis, Angela N., Roethka, Theresa J., Senger, Stefan, Stelman, Gary J., Toomey, John R., West, Robert I., Whittaker, Caroline, Zhou, Ping, Watson, Nigel S.

“…The discovery of potent series of orally available factor Xa inhibitors with aminoindane and phenylpyrrolidine motifs is described. The rational design,…”
Get full text

Structure and property based design of factor Xa inhibitors: Pyrrolidin-2-ones with biaryl P4 motifs by Young, Robert J., Borthwick, Alan D., Brown, David, Burns-Kurtis, Cynthia L., Campbell, Matthew, Chan, Chuen, Charbaut, Marie, Chung, Chun-wa, Convery, Máire A., Kelly, Henry A., Paul King, N., Kleanthous, Savvas, Mason, Andrew M., Pateman, Anthony J., Patikis, Angela N., Pinto, Ivan L., Pollard, Derek R., Senger, Stefan, Shah, Gita P., Toomey, John R., Watson, Nigel S., Weston, Helen E.

“…Structure and property based drug design was exploited in the synthesis of sulfonamidopyrrolidin-2-one-based factor Xa (fXa) inhibitors, incorporating biaryl…”
Get full text

Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs by Kleanthous, Savvas, Borthwick, Alan D., Brown, David, Burns-Kurtis, Cynthia L., Campbell, Matthew, Chaudry, Laiq, Chan, Chuen, Clarte, Marie-Olive, Convery, Máire A., Harling, John D., Hortense, Eric, Irving, Wendy R., Irvine, Stephanie, Pateman, Anthony J., Patikis, Angela N., Pinto, Ivan L., Pollard, Derek R., Roethka, Theresa J., Senger, Stefan, Shah, Gita P., Stelman, Gary J., Toomey, John R., Watson, Nigel S., West, Robert I., Whittaker, Caroline, Zhou, Ping, Young, Robert J.

“…The discovery of a potent series of orally available Factor Xa inhibitors with monoaryl P4 motifs is described. Structure and property based drug design was…”
Get full text

Structure and property based design of factor Xa inhibitors: Biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs by Young, Robert J., Borthwick, Alan D., Brown, David, Burns-Kurtis, Cynthia L., Campbell, Matthew, Chan, Chuen, Charbaut, Marie, Convery, Máire A., Diallo, Hawa, Hortense, Eric, Irving, Wendy R., Kelly, Henry A., King, N. Paul, Kleanthous, Savvas, Mason, Andrew M., Pateman, Anthony J., Patikis, Angela N., Pinto, Ivan L., Pollard, Derek R., Senger, Stefan, Shah, Gita P., Toomey, John R., Watson, Nigel S., Weston, Helen E., Zhou, Ping

“…Structure and property based drug design was exploited in the synthesis of sulfonamidopyrrolidin-2-one-based factor Xa (fXa) inhibitors, incorporating basic…”
Get full text

Selective and dual action orally active inhibitors of thrombin and factor Xa by Young, Robert J., Brown, David, Burns-Kurtis, Cynthia L., Chan, Chuen, Convery, Máire A., Hubbard, Julia A., Kelly, Henry A., Pateman, Anthony J., Patikis, Angela, Senger, Stefan, Shah, Gita P., Toomey, John R., Watson, Nigel S., Zhou, Ping

“…The synthetic entry to new classes of dual fXa/thrombin and selective thrombin inhibitors with significant oral bioavailability is described. The observed…”
Get full text

Antithrombotic Potential of GW813893: A Novel, Orally Active, Active-site Directed Factor Xa Inhibitor by Abboud, Melanie A, Needle, Saul J, Burns-Kurtis, Cynthia L, Valocik, Richard E, Koster, Paul F, Amour, Augustin J, Chan, Chuen, Brown, David, Chaudry, Laiq, Zhou, Ping, Patikis, Angela, Patel, Champa, Pateman, Anthony J, Young, Rob J, Watson, Nigel S, Toomey, John R

“…BACKGROUND:Factor Xa (FXa) has been a target of considerable interest for drug development efforts aimed at suppressing thrombosis. In this report, a new…”
Get full text

Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidone by SPETH, P. A. J, GORE, M. E, SMITH, I. E, MCVIE, J. G, DE MULDER, P. H. M, DE PAUW, B. E, GRIGGS, J. V, BROWN, G. W, PATEMAN, A. J, NEWELL, D. R, BISHOP, J. A. M, ELLIS, W. J, GREEN, J. A, GUMBRELL, L. A, LINSSEN, P. C. M, MILLER, A

“…Mitoquidone (MTQ) is the first member of a new group of pentacyclic pyrroloquinones developed for clinical evaluation as a potential anticancer agent. MTQ…”
Get full text